Market Place
Sourcing Support
NICE recommends siponimod for treating secondary progressive MS
15 Oct 2020 //
PHARMAFILE
Novartis data show early treatment with Mayzent delays disability progression
14 Sep 2020 //
PRESS RELEASE
Novartis Responds to NICE Decision on Siponimod
25 Jun 2020 //
PHARMTECH
China approves Novartis` multiple sclerosis treatment Mayzent
12 May 2020 //
REUTERS
Novartis Says New Mayzent Data Shows Sustained Effect In Delaying Disability
22 Apr 2020 //
REUTERS
Five-year data supports early treatment with Novartis` Mayzent
21 Apr 2020 //
PHARMAFILE
European Commission approves nintedanib for the treatment of systemic sclerosi
21 Apr 2020 //
APNEWS
Roche`s Ocrevus Continues to Impress in the EU with Strong Uptake
08 Apr 2020 //
PR NEWSWIRE
Novartis announces EU approval of Mayzent
21 Jan 2020 //
GLOBENEWS WIRE
Novartis hopes for 25 more blockbuster nods in the coming years
05 Dec 2019 //
FIERCE PHARMA
Novartis receives positive CHMP opinion for Mayzent® (siponimod)
15 Nov 2019 //
BUSINESS WIRE
Merck KGaA`s MS launch Mavenclad offsets Rebif sales shortfall
14 Nov 2019 //
FIERCE PHARMA
Novartis’ Zolgensma smashes sales estimates
22 Oct 2019 //
FIERCE PHARMA
Merck KGaA touts Mavenclad data as MS new drug race heats up
14 Sep 2019 //
FIERCE PHARMA
J&J`s head-to-head PhIII data promise drug launch into crowded MS market
13 Sep 2019 //
ENDPOINTSNEWS
Novartis reports positive Phase III data for multiple sclerosis drug
03 Sep 2019 //
CLINICALTRIALSARENA
Novartis` repurposed cancer drug Arzerra outpaces Sanofi`s Aubagio in MS trial
31 Aug 2019 //
FIERCE PHARMA
AllianceRx Walgreens Prime Issues Updated List of New Specialty Drugs
16 Aug 2019 //
PR NEWSWIRE
Novartis Gilenya staves off geric challengers? - for now.
26 Jun 2019 //
FIERCE PHARMA
Cost-effectiveness watchdogs skewer J&J`s depression spray Spravato
22 Jun 2019 //
FIERCE PHARMA
Novartis finds PhIII data to assert Mayzent boosts cognition in MS patients
09 May 2019 //
ENDPTS
Novartis` new Mayzent helps MS patients think faster: study
09 May 2019 //
FIERCE PHARMA
FDA Raises Concerns With Novartis in Clinical Inspection
07 May 2019 //
RAPS
FDA approves new oral drug to treat multiple sclerosis
26 Mar 2019 //
PR NEWSWIRE
Blockbuster to be? Novartis snags a major win as FDA OKs late-stage drugs
26 Mar 2019 //
ENDPTS
Novartis CEO Vas Narasimhan lines up his late-stage blockbuster contenders
06 Nov 2018 //
ENDPTS
Novartis bets PRV on next big MS drug — eyes approvals in ’19
09 Oct 2018 //
ENDPTS
Novartis announces positive results from phase III EXPAND study of oral
20 Apr 2018 //
PHARMABIZ
Novartis Published Multiple Sclerosis Trial Data, Plans FDA Approval Filing
26 Mar 2018 //
BIOSPACE
US, EU filings imminent for Novartis’ MS therapy siponimod
23 Mar 2018 //
PHARMA TIMES
Ph3 data in The Lancet shows Novartis siponimod improved MS patient outcomes
22 Mar 2018 //
PR NEWSWIRE
